Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report

A 47‐year‐old female with ALK‐rearranged lung adenocarcinoma developed leptomeningeal metastasis (LM) after progression on first‐line crizotinib. Alectinib 300 mg was commenced and the patient achieved clinical and radiographic improvements. After nine months of alectinib 300 mg, she started to expe...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Zhaona Li, Pupu Li, Bing Yan, Qiongqiong Gao, Xiangli Jiang, Zhongli Zhan, Qingna Yan, Analyn Lizaso, Chun Huang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2020-01-01
coleção:	Thoracic Cancer
Assuntos:	Alectinib dose escalation ALK rearrangement cerebrospinal fluid leptomeningeal metastasis non‐EML4‐ALK
Acesso em linha:	https://doi.org/10.1111/1759-7714.13259
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!